Sinovac Biotech Ltd SVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SVA is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.00
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- $0.00
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 23.52
- Price/Sales
- 1.83
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sinovac Biotech Ltd is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including, without limitation, hepatitis A, hepatitis B, hand foot and mouth disease (HFMD) caused by EV71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 3,261
- Website
- http://www.sinovac.com
Comparables
Valuation
|
Metric
|
SVA
|
01099
|
002880
|
|---|---|---|---|
Price/Earnings (Normalized) | 23.52 | 5.97 | 30.52 |
Price/Book Value | 1.82 | 0.70 | 2.98 |
Price/Sales | 1.83 | 0.09 | 5.76 |
Price/Cash Flow | 8.10 | 2.91 | 18.34 |
Price/Earnings
SVA
01099
002880
Financial Strength
|
Metric
|
SVA
|
01099
|
002880
|
|---|---|---|---|
Quick Ratio | 10.17 | 1.05 | 1.50 |
Current Ratio | 10.31 | 1.39 | 3.83 |
Interest Coverage | −104.38 | 7.35 | 14.52 |
Quick Ratio
SVA
01099
002880
Profitability
|
Metric
|
SVA
|
01099
|
002880
|
|---|---|---|---|
Return on Assets (Normalized) | −0.95% | 4.43% | 7.55% |
Return on Equity (Normalized) | −1.51% | 24.34% | 10.65% |
Return on Invested Capital (Normalized) | −1.55% | 9.74% | 8.73% |
Return on Assets
SVA
01099
002880
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Dysdmmxvm | Nphr | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Bztbpltx | Xspthy | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Twfwdspj | Dgbgdj | $118.7 Bil | |||
| Moderna Inc
MRNA
| Hrtdzsgd | Gjzpc | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zhvxrdmvl | Vpnzqf | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Zxsmjht | Ggcjv | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Sshxrfh | Krd | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gtqqfqmbk | Qsyxcgr | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Hkyrbcjf | Yjh | $15.0 Bil | |||
| Incyte Corp
INCY
| Qtqdjcw | Shnxfm | $13.5 Bil |